Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-187-3p mimic
- Development stage
- Preclinical
- Lead developer
- RiboBio
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
miR-187-3p mimic is a chemically synthesized, double-stranded RNA molecule designed to mimic the biological function of the endogenous microRNA miR-187-3p. As a microRNA agonist, it functions by binding to the 3' untranslated regions (UTRs) of specific messenger RNAs (mRNAs), leading to their degradation or the inhibition of their translation. In preclinical research, this mimic has been utilized to study its tumor-suppressive or protective effects in various conditions, including prostate cancer, clear cell renal cell carcinoma, colorectal cancer, and ischemia-reperfusion injury. It targets several genes depending on the disease context, such as FGFRL1, P2X7R, LRFN1, SPRY1, Seipin, and NIPBL. Currently, miR-187-3p mimic is used exclusively as a laboratory research tool and is not an approved therapeutic agent or a candidate in clinical trials.
- Other names
- microRNA-187-3p mimicmicroRNA187-3p mimicmicroRNA 187-3p mimichsa-miR-187-3p mimichsa-miR187-3p mimichsa-miR 187-3p mimic
02
Targets
Cannabinoid receptor 2 mRNA 3' untranslated regionFibroblast growth factor receptor-like 1 mRNA 3' untranslated regionLeucine-rich repeat and fibronectin type III domain-containing protein 1 mRNA 3' untranslated regionP2X purinoceptor 7 mRNA 3' untranslated regionBCL6 (B cell lymphoma 6 protein)NIPBL (NIPBL / Cornelia de Lange protein)Berardinelli-Seip congenital lipodystrophy 2 mRNA 3' untranslated region (BSCL2 mRNA 3'UTR)SPRY1 (Sprouty homolog 1)
Beyond the preview
Go deeper on miR-187-3p mimic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-187-3p mimic.